United Laboratories International (ULIHF) Stock Price, News & Analysis

Company Overview

The United Laboratories International Holdings Limited, an investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, amoxicillin products, nervous system drugs, vitamins, veterinary drugs, and vacant gelatin capsules. It also provides intermediate products, such as 6-aminopenicillanic acid, tert-octylammonium clavulanate, anhydrous sodium carbonate sterile, and penicillin G potassium first crystal. In addition, the company manufactures and sells soft capsules casings; holds trademarks; and trades in pharmaceutical products, as well as offers management services. It has operations in the People's Republic of China, India, Europe, the Middle East, South America, rest of Asian regions, and internationally. The company was founded in 1990 and is headquartered in Yuen Long, Hong Kong.

Key Stats

• Today's Range: $1.78 to $1.78
• 50-Day Range: $1.40 to $2.35
• 52-Week Range: $1.15 to $2.35
• Volume: 200 shs
• Average Volume: 9,818 shs
• Market Capitalization: N/A
• P/E Ratio: 4.04
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

United Laboratories International Stock Analysis - MarketRank™

United Laboratories International scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for United Laboratories International.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of United Laboratories International is 4.04, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 22.74.

Price to Earnings Ratio vs. Sector

The P/E ratio of United Laboratories International is 4.04, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.13.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

United Laboratories International has a short interest ratio ("days to cover") of 331.2, which indicates bearish sentiment.

Change versus previous month

Short interest in United Laboratories International has recently increased by 98.71%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

United Laboratories International does not currently pay a dividend.

Dividend Growth

United Laboratories International does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

United Laboratories International has a short interest ratio ("days to cover") of 331.2, which indicates bearish sentiment.

Change versus previous month

Short interest in United Laboratories International has recently increased by 98.71%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.0 / 5
• News Sentiment: -0.22

News Sentiment

United Laboratories International has a news sentiment score of -0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for United Laboratories International this week, compared to 3 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, United Laboratories International insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 2.61% of the stock of United Laboratories International is held by institutions.

ULIHF Stock Analysis - Frequently Asked Questions

How have ULIHF shares performed this year?

United Laboratories International's stock was trading at $1.25 at the beginning of 2025. Since then, ULIHF shares have increased by 42.0% and is now trading at $1.7750.
View the best growth stocks for 2025 here.

How do I buy shares of United Laboratories International?

Shares of ULIHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:ULIHF
• CIK: N/A
• Web: www.tul.com.cn
• Phone: 852-2687-1033
• Fax: N/A
• Employees: 15,000
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: 4.04
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A